Pharvaris N.V.

DB:9EN Stock Report

Market Cap: €946.5m

Pharvaris Valuation

Is 9EN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 9EN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 9EN (€17.8) is trading below our estimate of fair value (€97.19)

Significantly Below Fair Value: 9EN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 9EN?

Key metric: As 9EN is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 9EN. This is calculated by dividing 9EN's market cap by their current book value.
What is 9EN's PB Ratio?
PB Ratio3.4x
Book€296.79m
Market Cap€946.54m

Price to Book Ratio vs Peers

How does 9EN's PB Ratio compare to its peers?

The above table shows the PB ratio for 9EN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.1x
DMP Dermapharm Holding
3.7x17.3%€2.2b
PSG PharmaSGP Holding
8.6x13.6%€316.5m
2FJ0 Pierrel
3.6xn/a€92.8m
93M1 MPH Health Care
0.3x-65.7%€101.0m
9EN Pharvaris
3.4x31.4%€979.4m

Price-To-Book vs Peers: 9EN is good value based on its Price-To-Book Ratio (3.4x) compared to the peer average (4.1x).

Price to Book Ratio vs Industry

How does 9EN's PB Ratio compare vs other companies in the European Pharmaceuticals Industry?

9 CompaniesPrice / BookEstimated GrowthMarket Cap
9EN 3.4xIndustry Avg. 2.2xNo. of Companies17PB01.63.24.86.48+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 9EN is expensive based on its Price-To-Book Ratio (3.4x) compared to the European Pharmaceuticals industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is 9EN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

9EN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 9EN's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 9EN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€17.80
€32.90
+84.8%
30.2%€43.68€13.27n/a7
Jan ’26€18.20
€32.90
+80.8%
30.2%€43.68€13.27n/a7
Dec ’25€20.20
€33.10
+63.9%
30.7%€45.10€13.27n/a7
Nov ’25€22.00
€32.16
+46.2%
31.1%€45.10€12.74n/a7
Oct ’25€16.00
€31.88
+99.3%
31.4%€45.10€12.74n/a7
Sep ’25€16.10
€29.84
+85.3%
32.5%€45.35€12.74n/a6
Aug ’25€14.30
€31.18
+118.0%
32.2%€45.95€12.07n/a6
Jul ’25€17.20
€30.76
+78.9%
32.2%€45.95€12.07n/a6
Jun ’25€17.00
€30.84
+81.4%
32.5%€46.41€12.07n/a6
May ’25€22.40
€31.04
+38.6%
32.7%€46.69€11.94n/a6
Apr ’25€21.20
€31.32
+47.8%
31.3%€45.07€11.94n/a6
Mar ’25€21.40
€31.51
+47.2%
31.2%€45.17€11.94n/a6
Feb ’25€27.00
€28.98
+7.3%
37.3%€45.00€11.94n/a7
Jan ’25€25.00
€27.28
+9.1%
35.4%€37.06€10.20€18.207
Dec ’24€15.80
€20.42
+29.3%
32.6%€29.49€7.48€20.207
Nov ’24€15.80
€21.08
+33.4%
34.5%€31.26€7.33€22.007
Oct ’24€19.10
€20.84
+9.1%
34.5%€31.26€7.33€16.007
Sep ’24€18.90
€20.06
+6.1%
37.3%€31.26€7.33€16.106
Aug ’24€15.20
€15.83
+4.1%
38.6%€23.73€7.37€14.306
Jul ’24€14.00
€15.88
+13.4%
38.4%€23.73€7.37€17.206
Jun ’24€8.20
€14.67
+78.8%
34.8%€22.17€7.37€17.006
May ’24€8.30
€14.85
+79.0%
35.1%€22.77€7.59€22.406
Apr ’24€7.35
€15.51
+111.0%
36.9%€22.77€7.59€21.206
Mar ’24€7.65
€15.51
+102.7%
36.9%€22.77€7.59€21.406
Feb ’24€8.40
€15.74
+87.4%
36.6%€22.77€7.59€27.006
Jan ’24€10.30
€15.82
+53.6%
35.7%€22.77€7.59€25.006

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 01:12
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pharvaris N.V. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Alexandru CogutBryan Garnier & Co
Jonathan WollebenJMP Securities